Steno Diabetes Centre and Hagedorn Research Institute, Gentofte, Denmark.
BMC Med Genet. 2010 Mar 12;11:42. doi: 10.1186/1471-2350-11-42.
BACKGROUND: Insulin gene (INS) mutations have recently been described as a common cause of permanent neonatal diabetes (PNDM) and a rare cause of diabetes diagnosed in childhood or adulthood. METHODS: INS was sequenced in 116 maturity-onset diabetes of the young (MODYX) patients (n = 48 Danish and n = 68 Czech), 83 patients with gestational diabetes mellitus (GDM), 34 type 1 diabetic patients screened negative for glutamic acid decarboxylase (GAD), and 96 glucose tolerant individuals. The control group was randomly selected from the population-based sampled Inter99 study. RESULTS: One novel heterozygous mutation c.17G>A, R6H, was identified in the pre-proinsulin gene (INS) in a Danish MODYX family. The proband was diagnosed at 20 years of age with mild diabetes and treated with diet and oral hypoglycaemic agent. Two other family members who carried the INS R6H were diagnosed with diabetes when 51 years old and with GDM when 27 years old, respectively. A fourth mutation carrier had normal glucose tolerance when 20 years old. Two carriers of INS R6H were also examined twice with an oral glucose tolerance test (OGTT) with 5 years interval. They both had a approximately 30% reduction in beta-cell function measured as insulinogenic index. In a Czech MODYX family a previously described R46Q mutation was found. The proband was diagnosed at 13 years of age and had been treated with insulin since onset of diabetes. Her mother and grandmother were diagnosed at 14 and 35 years of age, respectively, and were treated with oral hypoglycaemic agents and/or insulin. CONCLUSION: Mutations in INS can be a rare cause of MODY and we conclude that screening for mutations in INS should be recommended in MODYX patients.
背景:胰岛素基因 (INS) 突变最近被描述为导致永久性新生儿糖尿病 (PNDM) 的常见原因,也是导致儿童或成年期诊断出的糖尿病的罕见原因。
方法:对 116 例青年发病的成年型糖尿病 (MODYX) 患者(48 例丹麦患者和 68 例捷克患者)、83 例妊娠期糖尿病 (GDM) 患者、34 例谷氨酸脱羧酶 (GAD) 阴性的 1 型糖尿病患者和 96 例葡萄糖耐量正常个体进行了 INS 测序。对照组是从基于人群的 Inter99 研究中随机选择的。
结果:在一个丹麦 MODYX 家族中,我们在胰岛素前胰岛素基因 (INS) 中发现了一个新的杂合突变 c.17G>A,R6H。先证者在 20 岁时被诊断为轻度糖尿病,仅接受饮食和口服降糖药物治疗。携带 INS R6H 的另外两名家族成员分别在 51 岁和 27 岁时被诊断为糖尿病和 GDM。第四名 INS R6H 携带者在 20 岁时葡萄糖耐量正常。两名 INS R6H 携带者还接受了两次口服葡萄糖耐量试验 (OGTT),两次检查之间间隔 5 年。他们的胰岛β细胞功能均下降约 30%,表现为胰岛素原指数降低。在一个捷克 MODYX 家族中,我们发现了先前描述的 R46Q 突变。先证者在 13 岁时被诊断出患有糖尿病,此后一直接受胰岛素治疗。她的母亲和祖母分别在 14 岁和 35 岁时被诊断出患有糖尿病,接受了口服降糖药物和/或胰岛素治疗。
结论:INS 突变可能是 MODY 的罕见病因,我们认为应建议对 MODYX 患者进行 INS 突变筛查。
Clin Endocrinol (Oxf). 2011-10
Diabetol Int. 2025-3-14
BMJ Open Diabetes Res Care. 2024-12-20
Front Endocrinol (Lausanne). 2022
Front Endocrinol (Lausanne). 2022
Front Endocrinol (Lausanne). 2021
Nat Clin Pract Endocrinol Metab. 2008-4
Proc Natl Acad Sci U S A. 2007-9-18
Eur J Cardiovasc Prev Rehabil. 2003-10